

Review

Saliva Metabolomic Profile in Dental Medicine Research: A Narrative Review

Konstantinos Tzimas *  and Eftychia Pappa 

Department of Operative Dentistry, School of Dentistry, National and Kapodistrian University of Athens, 11527 Athens, Greece

* Correspondence: kwstastzimas@dent.uoa.gr

Abstract: Metabolomic research tends to increase in popularity over the years, leading to the identification of new biomarkers related to specific health disorders. Saliva is one of the most newly introduced and systematically developed biofluids in the human body that can serve as an informative substance in the metabolomic profiling armamentarium. This review aims to analyze the current knowledge regarding the human salivary metabolome, its alterations due to physiological, environmental and external factors, as well as the limitations and drawbacks presented in the most recent research conducted, focusing on pre—analytical and analytical workflows. Furthermore, the use of the saliva metabolomic profile as a promising biomarker for several oral pathologies, such as oral cancer and periodontitis will be investigated.

Keywords: metabolomics; saliva; biofluid; metabolome; biomarker; oral cancer; periodontitis



Citation: Tzimas, K.; Pappa, E. Saliva Metabolomic Profile in Dental Medicine Research: A Narrative Review. *Metabolites* **2023**, *13*, 379. <https://doi.org/10.3390/metabo13030379>

Academic Editor: Arja Kullaa

Received: 7 February 2023

Revised: 28 February 2023

Accepted: 1 March 2023

Published: 3 March 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Saliva is the readily accessible biological fluid of the oral cavity [1]. It is produced by three major pairs of glands and hundreds of minor ones. The three major glands participating in the production of saliva are the parotid, submandibular and sublingual glands, which lead to the classification of parotid saliva, submandibular saliva and sublingual saliva respectively [2]. Additional classification of the secretion of saliva is based on the presence or absence of stimuli leading to its production. More precisely, at rest, *unstimulated saliva* is produced with its major portion originating from the submandibular glands (almost 70%), whereas *stimulated saliva*, induced by stimuli such as smell, taste or drugs originates primarily from the parotid glands [1,3].

The term “whole mouth saliva” (WMS) is used in oral sciences to determine the transparent, clear, watery fluid composed by a mixture of the parotid saliva, the submandibular saliva and the sublingual saliva, combined with the secretions of minor salivary glands, the gingival crevicular fluid, eukaryotic cells (epithelial as well as leukocytic), food debris, microorganisms and their metabolites [4–6].

Due to its aqueous composition, saliva mainly consists of water (99% of its composition). Further components, such as mucus, digestive enzymes, growth factors, cytokines, immunoglobulins, antibacterial peptides, salts and low molecular weight metabolites are numbered among salivary products [7].

The average healthy person generates 0.75 to 1.5 L of saliva per day, with a greater volume secreted when the person is awake [8]. There is an evident differentiation in the composition, flow rate and volume of saliva both between individuals and within the same individual [9]. These variations depend on stimuli delivered by the sympathetic and parasympathetic systems of the autonomic nervous system (neural control) [10], as well as on physical, environmental and/or pathological factors, which include circadian rhythm, age, gender, physical exercise, oral hygiene, food consumption, medication and systematic diseases [11] (Figure 1). Among its functions, lubrication and moisturization of the surfaces of the oral cavity, the pharynx and the esophagus, oral digestion, tissue and tooth integrity

protection and antibacterial and antiviral defense, play a pivotal role in oral homeostasis and in the overall quality of life [12,13].




Figure 1. Whole Mouth Saliva components and factors affecting its composition.

Biotechnological advances and applications in the health sciences have led to the introduction of “omics” in medicine. Genomics, studying the structure, function, evolution and mapping of genes and transcriptomics, the field of biological study of mRNA molecules led to the formation of the appropriate conditions for circumstantial monitoring of smaller organ and/or cell compounds such as proteins (proteomics) and low molecular weight metabolites (metabolomics) [14,15].

A metabolite is a small molecule with a molecular weight typically less than 1500 Da [16]. The complete set of small molecular metabolites is called the “metabolome” [17]. “Metabolomics” is defined as the latest of the –omics technologies, investigating metabolites within biofluids, cells and tissues [18].

The use of biofluids in the human body such as serum, plasma, urine and cerebrospinal fluid for metabolomic profiling on a variety of health disorders including cancer, infectious diseases, neurological diseases (Alzheimer’s disease, dementia) cardiovascular, rheumatological, renal, and respiratory diseases is scientifically established and acceptable [19]. On the contrary, scarce evidence is present when addressing salivary metabolites [20]. The salivary metabolome is considered as a critical asset in elucidating pathways identifying various local and systematic disorders, and it may be used as a key mediator in treatment design and modification as well as in treatment outcomes [21].

The aim of this narrative review is firstly, to shed light on the importance of the human salivary metabolome in health, secondarily to assess the analytical protocols and the

limitations of salivary metabolomic studies and lastly to analyze the salivary metabolomic profile as a possible, sufficient and powerful biomarker of oral pathogenesis.

2. Human Salivary Metabolome Research and Its Limitations

A lot of studies focus on metabolite profiling in blood and urine, whereas scientific evidence for metabolic profiling in saliva is lacking. Takeda et al., concluded that the saliva metabolome proved to be comparable to the human serum and cerebrospinal fluid metabolomes in terms of chemical composition, strengthening the belief of homogeneity of compounds found in human saliva and human blood, independently of their different concentrations [20]. The well known positive correlation between salivary and plasma metabolite levels (e.g., glucose, lactate and pyruvate), as well as the fact that the proteomic and metabolomic alterations observed in saliva follow a similar pattern to the changes seen in blood, reinforce the use of saliva as an informative diagnostic biofluid [22,23].

Among the benefits of saliva are its ad libitum production, non-invasiveness, painlessness, relatively fast and cheap collection, minimal collector training, reduced anxiety when compared to blood collection and child friendlier approach when compared to blood collection, making it the perfect, informative, most readily available biofluid [5,24–26]. The convenient analysis of saliva samples, the non-infectious collection process, the ease of its transportation and its disposable nature are further positive aspects of using saliva for metabolite profiling processes [27].

Most salivary metabolomic research on healthy subjects focuses on the identification of specific metabolites or metabolic species. This kind of research is characterized as *targeted salivary metabolomic research* [23]. The first important *non—targeted metabolomic analysis of saliva* was conducted by Silwood et al., in 2002, who identified more than 60 metabolites and quantified 11 salivary metabolites in healthy human saliva, along with an interesting intra and inter—subject variability in the concentrations of these molecules [28]. Likewise, Sugimoto et al. (2013) identified and quantified 148 salivary metabolites in healthy humans [29]. Dame et al. (2015) accomplished the identification and the quantification of a total of 308 salivary metabolites in healthy people [23]. Nowadays, more than 853 identified and quantified salivary metabolites or metabolite species are freely available at the Human Metabolome Database (HMDB) [30].

All salivary metabolomic research studies (either targeted or non-targeted) of healthy human samples, focus on multiple factors that tend to modify the concentration of the healthy saliva metabolome. The greatest factors affecting the healthy human saliva metabolome are: *the collection method*, where stimulated saliva presents a decrease in metabolite concentrations compared to unstimulated whole mouth saliva secretion samples [20]; *the type of the gland that the saliva is secreted from*, since submandibular gland saliva is more viscous than the serous parotid gland saliva [30]; *the gender*, where acetate, formate, glycine, lactate, methanol, propionate, propylene glycol, pyruvate and taurine were significantly higher in concentration in male rather than in female saliva samples [20,31], *the smoking status*, that leads to up- and/or down-regulations of metabolic concentrations [32], *the diurnal cycle* (circadian cycle), where specific salivary metabolites—mainly amino-acids- showed a clear diurnal variation in their concentration [33], *the fasting conditions (diet)*, where longer time period between last diet and sample collection affected the salivary metabolomic profile [23,34] and the *microflora* of the oral cavity, but most precisely the *host-microbiome interactions*. The oral microbiome strongly affects the net metabolic composition of the WMS at rest and can lead to alterations in its composition upon exposure to exogenous substances. The updated literature indicates that certain WMS metabolites including short chain fatty Acids (SCFAs), are absent from the sterile parotid gland saliva, leading to the conclusion that some saliva metabolites present a strong correlation with the bacterial index of the WMS. Furthermore, the metabolic patterns of the WMS present greater inter—individual variations than those of plasma metabolites, possibly caused by the existence of diversity in the oral microbiota that modulates the WMS metabolites. Conversely, plasma metabolites are easily regulated due to host mechanisms [26,35,36]. A field of further investigation

involves the reflection of the oral microbiome on the salivary metabolome, as well as the dynamic interactions of different biofluids.

From a technical point of view, several analytical platforms are developed and integrated into the human saliva metabolomic profiling process. The two most renowned metabolite measurement technologies are nuclear magnetic resonance spectroscopy (HNMR) and mass spectrometry (MS) [20,23,24,37,38]. Subcategories of MS methods or additional combinatorial/conjunctive methods are mentioned below. Capillary electrophoresis time-of-flight mass spectrometry (CE-TOF-MS), gas-chromatography mass spectrometry (GC-MS), direct flow injection—liquid chromatography mass spectrometry (LC-MS), inductively coupled plasma mass spectrometry (ICP-MS) and high performance liquid chromatography (HPLC) [23,39,40]. The description of each analytical platform is outside the scope of this mini-review. NMR is characterized as an untargeted metabolomics technique that leads to the identification and quantification of compounds, including short-chain organic acids, amino acids, alcohols, amines, sugars and pharmaceutical adjuvants. The advantage of this technique focuses on the minimal or no sample pre-treatment needed (deproteinization by centrifuging) and on its higher reproducibility compared to MS analytical platforms [41]. On the other hand, MS is an analytical method of high sensitivity, that identifies and/or quantifies a substance by measuring its mass and number of ions by the use of various ionization methods [42]. The combination of MS with other conjunctive methods has the advantage of greater metabolite identification even at lower concentrations [43–45]. The use of complex extraction methods and separation steps in order to detect and analyze both polar and non-polar organic acids is highlighted as a difficulty that complicates the identification procedure by mass spectrometry [41]. MS-based metabolomics require a well-designed pooled quality control sample (PQC) that is repeatedly analyzed throughout the sample batch and used for signal corrections compared to NMR-based metabolomic analysis [18,46]. Those characteristics are mentioned in order to understand that an additional limitation in salivary metabolomic studies exists due to the complexity of the analytical instruments used. Most studies only use one analytical platform and try to analyze one individual metabolome, which makes a potential comparison of salivary metabolic profiles between studies using different analytical technologies insignificant. At this point the allusion to the term “*standard operating procedure*” is of utmost importance (Figure 2). This term refers to the standardization and enactment of specific workflows as to the pre-analytical, analytical and post-analytical methods used [47,48]. The standardization of sample collection (for example, the use of unstimulated WMS in all studies), sample storage conditions (freezing temperatures), sample pretreatment (centrifugation for cell content removal and/or additional separation steps), sample analysis (by the use of more than one analytical platform) and statistical methods employed (principal component analysis—partial least-squares regression) would minimize the heterogeneous results in salivary metabolomic coverage [13,25,26], caused by separation difficulties, sensitivity differences, instrument detection differences, compound stability, solubility, and volatility [23,49,50], and give the opportunity to conduct comprehensive systematic reviews and meta-analyses, which are placed on top of the evidence-based science pyramid (Figure 3). Scientific studies are categorized based on the quality as well as the amount of evidence available, meaning that towards the base of the pyramid, the amount of evidence increases but simultaneously the quality of the evidence decreases.




Figure 2. Limitations of saliva metabolomic profile studies.




Figure 3. The evidence—based pyramid.

3. The Human Salivary Metabolome and Oral Pathologies

According to the World Health Organization (WHO), a “biomarker” is defined as any substance, structure, or process that can be measured in the body or in its products and that can influence or predict the incidence of an outcome or disease [51]. Over the years, clinical studies have focused on detecting specific salivary metabolites associated with specific oral diseases, thus characterizing these metabolites as diagnostic biomarkers. This remains questionable, as one salivary metabolite’s quantitative alteration may simply indicate a non-specific pathological shift, incidental to insufficient diagnostic specificity. On the other hand, multivariate analysis may offer greater accuracy for putative biomarker findings [26]. The early “fingerprints” of changes in a wide range of diseases could be discovered by the study of the metabolic profile of saliva. Focusing on oral pathology and its association with salivary metabolomics, efforts have been made in the fields of oral cancer and periodontal diseases.

As mentioned by Khurshid et al., in 2018, oral cancer is the 6th most common cancer worldwide, and its late detection is highly associated with its high mortality and morbidity rates. Approximately 60–80% of patients with oral cancer are diagnosed at a late-stage. Hundreds of salivary biomarkers (using genomics, transcriptomics and proteomics) have

already been identified, including cytokines (IL-8, IL-1b, TNF- α), defensin-1, P53, tissue polypeptide-specific antigen, dual specificity phosphatase, profilin, cofilin-1, transferrin etc. [52]. Human saliva metabolomics and its contribution to oral cancer diagnosis is a field of continuous investigation, since saliva is in direct contact with the mucosa and cancerous cells of the oral cavity. The validation of specific saliva metabolomic biomarkers for oral cancer may lead to early stage detection and a more appropriate treatment modality for the patient [13,21,25,26]. Several studies, with different protocols, conducted over the last few years identified different saliva metabolite concentrations either between healthy controls and oral squamous cell carcinoma subjects or between OSCC subjects and premalignant lesion subjects (oral lichen planus, oral leukoplakia, precancerous dysplasia, keratosis). Their samples, analytical and discrimination methods and outcomes are summarized in Table 1 [53–67]. A notable diversity of candidate biomarkers is presented in these studies. More precisely, Sugimoto et al. (2010) [55] and Wang et al. (2014) [57,58] both mentioned increased choline and betaine and decreased L-carnitine in patients with OSCC compared to healthy controls. Choline is also found among other metabolites as a potential biomarker in the research of Ohshima et al., in 2017 [60]. Glycine, proline and ornithine were found in three independent studies by Lohavanichbutr et al. (2018), Ishakawa et al. (2019) and Tantray et al. (2022) as potential oral cancer biomarkers [61,62,67]. However, different studies identified different groups of metabolites that were either upregulated or downregulated in OSCC and precancerous samples compared to healthy controls. These deviations are associated with limitations concerning sample size, population tested, and analytical methods used—factors that lead to heterogeneous results despite the similar study designs of the studies. The limitations of this kind of study lie in two factors: firstly, the evaluation of the specificity of the salivary metabolite biomarker against other inflammatory diseases, for instance, periodontitis, because a possible overlap in the metabolite biomarkers between periodontitis and oral cancer could lead to serious misdiagnosis, and secondarily, the study design, the analytical instruments used, the discrimination methods, and the absence of cross-validation of the analytical equipment between different laboratories [13].

The same opportunities, but simultaneously the same concerns, are detected in the use of salivary metabolites in periodontitis diagnosis and treatment. Periodontal diseases are characterized as one of the two main causes of tooth loss and are inextricably linked to connective tissue loss, periodontal pocket formation, and progressive bone degradation [21,68]. The development of new saliva metabolite biomarkers may eliminate tooth loss due to early diagnosis of the severity of the periodontal condition. In several studies that are listed in Table 2, an upregulation or downregulation of specific salivary metabolite species is detected (e.g., increased levels of fatty acids, phenylphenol, dipeptides leucylisoleucine, serylisoleucine, arachidonate, and dihomolinate) [55,69–83]. Besides saliva, the gingival crevicular fluid (GCF) is a great source of possible biomarkers for periodontal diseases. It includes a variety of host and microbial enzymes, endotoxins, nucleic acids, carbohydrates, lipids, degradation products of several metabolic pathways, cytokines and immunoglobulins. It is revealed that GCF is a more ideal biofluid for the diagnosis of periodontal diseases (and the differentiation of healthy patients, gingivitis patients, and periodontitis subjects) compared to serum and saliva, since it contains biomarkers that reflect inflammation, immune response and tissue destruction at the sight of periodontal lesions [84]. Metabolites associated with periodontal variables are clearly linked to tissue destruction, host defense mechanisms and bacterial metabolism [76]. When interpreting the presence of “salivary metabolites” in periodontitis patients, caution is needed, because they may be products of the developed microflora (oral microbiome metabolites). The bacterial metabolite phenylacetate is strongly correlated with periodontal disease. Salivary metabolomics may also be used as prognostic biomarkers of non-surgically and/or surgically treated periodontal disease. A change in the salivary metabolomic profile of a diseased patient after treatment entails the modification of a previously “diseased” specimen into a newly “healthy” one.

Table 1. Research focused on salivary metabolomics serving as biomarkers in oral cancer.

| Authors | Groups | Analytical Method | Discrimination Method | Observations—Candidate Biomarkers |
|-------------------------------------|--|---|--|--|
| Yan et al., 2008 [53] | Oral squamous cell carcinoma (OSCC)/ precancerous lesions | High performance liquid chromatography—mass spectrometry (HPLC—MS) | Multivariate hierarchical principle component analysis | |
| Jou et al., 2010 [54] | Healthy controls vs. oral cancer subjects | Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (TOF—MS) | Western plotting + immunoassays | Increased transferrin levels in oral cancer subjects + linear correlation between transferrin and stage of tumor |
| Sugimoto et al., 2010 [55] | Healthy controls vs. oral cancer vs. pancreatic cancer vs. breast cancer vs. periodontal disease | Capillary electrophoresis time-of-flight mass spectrometry (CE-TOF-MS) | Principal component analysis (PCA)/independent multiple logistic regression models (MLR) | Increased taurine, choline, and betaine Decreased pipecolinic acid and L-carnitine |
| Wei et al., 2011 [56] | Healthy controls vs. oral cancer vs. precancerous conditions | Ultraperformance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (LC—TOF—MS) | PCA/orthogonal partial least squares discriminant analysis | Increased valine, lactic acid and phenylalanine are the best combination of salivary biomarkers for the discrimination of oral cancer from precancerous conditions |
| Wang et al., 2014 [57] | Healthy controls vs. Stages I + II OSCC | LC—MS analysis | Multivariate data analysis | Increased choline, betaine and pipecolinic acid Decreased L—carnitine in OSCC |
| Wang et al., 2014 [58] | Follow-up study | Reverse-phase liquid and hydrophilic interaction chromatography and TOF—MS | Multivariate data analysis | Increased propionylcholine decreased N-actyl-L-phenylalanine, sphinganine, phytosphingosine and S-carboxymethyl-L-cysteine |
| Ishikawa et al., 2016 [59] | Healthy controls vs OSCC | CE—TOF—MS | MLR/support vector machine-feature selection/stepwise feature selection | Increased pipecolate and s-adenosylmethionine |
| Ohshima et al., 2017 [60] | Healthy controls vs. OSCC | CE—TOF—MS | Wilcoxon rank sum test | Increased choline, valine, isoleucine, leucine, 2-oxoisovaleric acid and 3-hydroxybutyric acid Decreased urea |
| Lohavanichbutr et al., 2018 [61] | Healthy controls vs. OSCC vs. oropharyngeal squamous cell carcinoma (OPSC) | Nuclear magnetic resonance spectroscopy (NMR), LC—MS, Quadrupole time-of-flight liquid chromatography—mass spectrometry (Q—TOF—LC—MS) | MLR | Decreased glycine, proline, citrulline, and ornithine were associated with early stage OSCC |

Table 1. Cont.

| Authors | Groups | Analytical Method | Discrimination Method | Observations—Candidate Biomarkers |
|----------------------------------|---|---|---------------------------------|---|
| Ishakawa et al., 2019 [62] | OSCC vs. oral epithelial dysplasia (OED) vs. persistent suspicious oral mucosal lesions (PSOML) | CE—TOF—MS | MLR | Decreased ornithine, carnitine, arginine, o-hydroxybenzoate, N-acetylglucosamine-1-phosphate, and ribose 5-phosphate (R5P) in OSCC/OED compared to PSOML |
| Shridharan et al., 2019 [63] | Healthy controls vs. oral leukoplakia vs. OSCC | Quadrupole time-of-flight liquid chromatography—mass spectrometry (Q—TOF—LC—MS) | ANOVA/chi—square tests | Increased 1-methylhistidine, inositol 1,3,4-triphosphate, d-glycerate-2-phosphate, 4-nitroquinoline-1-oxide, 2-oxoarginine, norcocaine nitroxide, sphinganine-1-phosphate, and pseudouridine in oral leukoplakia and OSCC decreased L-homocysteic acid, ubiquinone, neuraminic acid, and estradiol valerate. |
| Ishakawa et al., 2020 [64] | Healthy controls vs. oral cancer | 18F-FDG PET/CT | MLR | N-acetylneuraminate and 3-phenylpropionate can be used to discriminate between patients with oral cancer and controls |
| Song et al., 2020 [65] | Healthy controls vs. OSCC vs. premalignant lesions | Conductive polymer spray mass spectrometry (CPSI-MS) | Lasso regression model | Increased cadaverine, putrescine, spermidine, 5-aminopentanoic acid and proline in the OSCC group Decreased pipecolic acid, lysine, arginine, ornithine, and histidine in the OSCC group |
| De Sa Alves et al., 2021 [66] | Healthy controls vs. OSCC | Gas-chromatography mass spectrometry (GC-MS) | PCA, Wilcoxon—Mann Whitney test | Identification of 24 metabolites as candidate biomarkers. Increased malic acid, methionine, maltose, and inosine |
| Tantray et al., 2022 [67] | Healthy controls vs. oral leukoplakia vs. OSCC | GC—MS | | Increased decanedioic acid, 2-methyloctacosane, eicosane, octane, 3,5-dimethyl, pentadecane, hentriacontane, 5,5-diethylpentadecane, nonadecane, oxalic acid, 6-phenylundecane, l-proline, 2-furancarboxamide, 2-isopropyl-5-methyl-1-heptanol, pentanoic acid, docosane |

Table 2. Research focused on salivary metabolomics serving as biomarkers in periodontal disease.

| Authors | Groups | Analytical Method | Discrimination Method | Observations—Candidate Biomarkers |
|-------------------------------|---|---|--|---|
| Sugimoto et al., 2010 [55] | Healthy controls vs. oral cancer vs. periodontal disease vs. pancreatic cancer vs. breast cancer | CE-TOF-MS | MLR/PCA | There was no significant differences between patients with periodontal disease and healthy controls concerning oral polyamine levels. |
| Barnes et al., 2011 [69] | Healthy controls vs. periodontal specimens | UHPLC MS/MS + GC/MS | Welch's— <i>t</i> -test + false discovery rates | Increased dipeptides leucylisoleucine, phenylphenol, serylisoleucine, fatty acids, arachidonate, arachidate Many of these metabolites are the products of host-microbial metabolism. |
| Aimetti et al., 2012 [70] | Healthy controls vs. gingivitis vs. localized chronic periodontitis vs. generalized chronic periodontitis vs. localized aggressive periodontitis vs. generalized aggressive periodontitis | NMR | PCA, Projection to Latent Structure (PLS), Canonical Correlation Analysis (CA) | Metabolic profiles of generalized chronic periodontitis patients exhibited increased acetate, c-aminobutyrate, n-butyrate, succinate, trimethylamine, propionate, phenylalanine, and valine and decreased concentrations of pyruvate and N-acetyl groups in generalized chronic periodontitis |
| Huang et al., 2014 [71] | Patients with chronic periodontitis | Inductively coupled plasma mass spectrometry (ICP-MS)/GC-MS/LC-MS | Analysis of variance followed by Student's <i>t</i> -test. | Increased PGE2, PGD2, PGF2a, TXB2, 5-HETE, F2- isoprostane decreased PGI2, 13-HODE, and 9-HODE |
| Barnes et al., 2014 [72] | Diabetic and non-diabetic human subjects with a healthy periodontium, gingivitis and periodontitis | GC-MS/LC-MS | ANOVA/ <i>t</i> -tests/False discovery rate method | Comparison of healthy, gingivitis and periodontitis saliva samples within the non-diabetic group: Increased levels of oxidized glutathione and cysteine-glutathione disulfide, increased markers of oxidative stress, including increased purine degradation metabolites increased amino acid levels and increased ω -3 (docosapentaenoate) and ω -6 fatty acids (linoleate and arachidonate) |
| Kuboniwa et al., 2016 [73] | Periodontal inflamed surface area (PISA) before and after removal of supragingival plaque | GC-MS | OPLS | Increased cadaverine, 5-oxoproline, and histidine |

Table 2. Cont.

| Authors | Groups | Analytical Method | Discrimination Method | Observations—Candidate Biomarkers |
|-------------------------------|---|-------------------|--|---|
| Ozeki et al., 2016 [74] | GCF of moderate pockets vs. deep pockets vs. healthy controls | GC-MS | PCA | Increased putrescine, lysine, phenylalanine, ribose, taurine, 5-aminovaleric acid, and galactose in deep pocket sites |
| Rzeznick et al., 2017 [75] | Healthy controls vs. generalized periodontitis | NMR | PCA/OPLS | Increased short chain fatty acids such as butyrate. Decreased lactate, γ -amino-butyrate, methanol, and threonine |
| Liebsch et al., 2019 [76] | Age-stratified groups of oral health—correlation between metabolites and periodontal disease severity | LC-MS/MS | Linear regression analysis | Increased phenylacetate. |
| Singh et al., 2019 [77] | Surgically treated periodontal subjects vs. untreated periodontal patients | NMR | Multivariate and quantitative analysis | Increased lactate, ethanol, succinate, and glutamate in surgically treated periodontal subjects |
| Romano et al., 2019 [78] | Healthy controls vs. treated generalized chronic periodontitis | NMR | Univariate and multivariate paired approaches | The post-treatment metabolic profile of GCP patients could not be assimilated to that of healthy controls who exhibited different levels of lactate, pyruvate, valine, proline, tyrosine, and formate. |
| Gawron et al., 2019 [79] | Healthy control vs. chronic periodontitis | NMR | Multivariate analysis/OPLS | Increased lactate and isopropanol decreased glycerol, acetone and methanol |
| Schulte et al., 2020 [80] | Perinatally-acquired HIV patients vs. HIV-exposed, but uninfected patients and moderate periodontitis | LC-MS/MS | | Increased cadaverine particularly in HIV exposed but uninfected individuals with moderate periodontitis |
| Citterio et al., 2020 [81] | Healthy controls vs. untreated periodontitis vs. non surgically treated periodontal patients | NMR | Multivariate analysis/partial least squares (PLS)/OPLS | The post-NST metabolic profile of periodontal patients could not be completely assimilated to that of healthy controls. decreased leucine, valine, phenylalanine, isoleucine, hypoxanthine and uracil after non surgical treatment compared to untreated periodontitis |

Table 2. *Cont.*

| Authors | Groups | Analytical Method | Discrimination Method | Observations—Candidate Biomarkers |
|--------------------------------|---|-------------------|---|---|
| Rodrigues et al., 2021 [82] | Healthy controls vs. periodontal patients (over 65 years old) | GC-MS | Partial least squares analysis (PLS) | Increased 5-aminovaleric acid and serine in the gingival crevicular fluid |
| Overmyer et al., 2021 [83] | Supragingival dental plaque of healthy controls vs. periodontitis, vs. periodontitis + diabetes type 2 vs. periodontitis + prediabetes | GC-MS/LC-MS/MS | Generalized additive mixed-effect models/zero-adjusted Gamma distribution, log normal distribution, bimodal log normal distribution/log-likelihood ratio testing/Benjamini–Hochberg FDR correction | Increased phosphatidylcholines, plasmeynl phosphatidylcholines, ceramides containing non-OH fatty acids, and host proteins related to actin filament rearrangement |

4. Conclusions

Conclusively, salivary metabolomics form a promising newly established research field. The drawbacks of using saliva metabolites as putative biological indicators of oral or systematic health disorders focus on the small sample sizes of the studies conducted and on the great challenges of the implementation of these technologies into clinical diagnostics. The validation of salivary biomarkers may be accomplished by elevating metabolomic research from a “case-control-study” design to a “large-scale validation study” design. The simultaneous observation of salivary metabolomics and microbiomics would enlighten the pathogenetic mechanisms of oral diseases. The primary goal of salivary metabolomic profiling is to distinguish the type of inflammation itself and not to simply compare an inflammation status to that of a healthy control. Salivary metabolomics may open new horizons in clarifying pathogenesis, as well as in disease monitoring and treatment outcome assessment. Mapping the human saliva metabolome of individuals at many standpoints is equivalent to the establishment of more personalized treatment and follow-up protocols. All in all, the oral cavity is a complex organ with numerous factors affecting its salivary metabolic profile, a fact that may ramify accurate research findings.

Author Contributions: Conceptualization, K.T. and E.P.; validation, K.T. and E.P.; formal analysis, K.T.; investigation, K.T.; data curation, K.T.; writing—original draft preparation, K.T.; writing—review and editing, K.T. and E.P.; visualization, K.T.; supervision, E.P.; project administration, K.T. and E.P. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. de Almeida, P.D.V.; Gregio, A.M.T.; Machado, M.A.N.; de Lima, A.A.S.; Azevedo, L.R. Saliva composition and functions: A comprehensive review. *J. Contemp. Dent. Pract.* **2008**, *9*, 72–80.
2. Humphrey, S.P.; Williamson, R.T. A review of saliva: Normal composition, flow, and function. *J. Prosthet Dent.* **2001**, *85*, 162–169. [[CrossRef](#)] [[PubMed](#)]
3. Dodds, M.W.; Johnson, D.A.; Yeh, C.K. Health benefits of saliva: A review. *J. Dent.* **2005**, *33*, 223–233. [[CrossRef](#)] [[PubMed](#)]
4. Amerongen, A.V.; Veerman, E.C. Saliva—The defender of the oral cavity. *Oral Dis.* **2002**, *8*, 12–22. [[CrossRef](#)] [[PubMed](#)]
5. Pappa, E.; Kousvelari, E.; Vastardis, H. Saliva in the “Omics” era: A promising tool in paediatrics. *Oral Dis.* **2019**, *25*, 16–25. [[CrossRef](#)]
6. Proctor, G.B. The physiology of salivary secretion. *Periodontology* **2016**, *70*, 11–25. [[CrossRef](#)]
7. Soini, H.A.; Klouckova, I.; Wiesler, D.; Oberzaucher, E.; Grammer, K.; Dixon, S.J.; Xu, Y.; Brereton, R.G.; Penn, D.G.; Novotny, M.V. Analysis of volatile organic compounds in human saliva by a static sorptive extraction method and gas chromatography-mass spectrometry. *J. Chem. Ecol.* **2010**, *36*, 1035–1042. [[CrossRef](#)]
8. Sanchez-Pablo, M.A.; Gonzalez-Garcia, V.; del Castillo-Rueda, A. Study of total stimulated saliva flow and hyperpigmentation in the oral mucosa of patients diagnosed with hereditary hemochromatosis. Series of 25 cases. *Med. Oral Patol. Oral Cir. Bucal.* **2012**, *17*, e45–e49. [[CrossRef](#)]
9. Hsiao, Y.C.; Chu, L.J.; Chen, Y.T.; Chi, L.M.; Chien, K.Y.; Chiang, W.F.; Chang, Y.T.; Chen, S.F.; Wang, W.S.; Chuang, Y.N. Variability assessment of 90 salivary proteins in intraday and interday samples from healthy donors by multiple reaction monitoring-mass spectrometry. *Proteom.—Clin. Appl.* **2018**, *12*, 1700039. [[CrossRef](#)]
10. Proctor, G.B.; Carpenter, G.H. Regulation of salivary gland function by autonomic nerves. *Auton. Neurosci. Basic Clin.* **2007**, *133*, 3–18. [[CrossRef](#)]
11. Helmerhorst, E.J.; Dawes, C.; Oppenheim, F.G. The complexity of oral physiology and its impact on salivary diagnostics. *Oral Dis.* **2018**, *24*, 363–371. [[CrossRef](#)] [[PubMed](#)]
12. Hanning, C.; Hanning, M.; Kensche, A.; Carpenter, G. The mucosal pellicle—An underestimated factor in oral physiology. *Arch. Oral Biol.* **2017**, *80*, 144–152. [[CrossRef](#)] [[PubMed](#)]
13. Panneerselvam, K.; Ishikawa, S.; Krishnan, R.; Sugimoto, M. Salivary Metabolomics for Oral Cancer Detection: A Narrative Review. *Metabolites* **2022**, *12*, 436. [[CrossRef](#)] [[PubMed](#)]
14. Cuevas-Córdoba, B.; Santiago-García, J. Saliva: A fluid of study for OMICS. *OMICS* **2014**, *18*, 87–97. [[CrossRef](#)] [[PubMed](#)]

15. Kaczor-Urbanowicz, K.E.; Martin Carreras-Presas, C.; Aro, K.; Tu, M.; Garcia-Godoy, F.; Wong, D.T. Saliva diagnostics—Current views and directions. *Exp. Biol. Med.* **2017**, *242*, 459–472. [CrossRef]
16. Chaleckis, R.; Meister, I.; Zhang, P.; Wheelock, C.E. Challenges, progress and promises of metabolite annotation for LC-MS-based metabolomics. *Curr. Opin. Biotechnol.* **2019**, *55*, 44–50. [CrossRef]
17. Wong, D.T. Salivaomics. *J. Am. Dent. Assoc.* **2012**, *143*, 19–24. [CrossRef]
18. Hynne, H.; Sandås, E.M.; Elgstøen, K.B.P.; Rootwelt, H.; Utheim, T.P.; Galtung, H.K.; Jensen, J.L. Saliva Metabolomics in Dry Mouth Patients with Head and Neck Cancer or Sjögren’s Syndrome. *Cells* **2022**, *11*, 323. [CrossRef]
19. Evans, E.D.; Duvallet, C.; Chu, N.D.; Oberst, M.K.; Murphy, M.A.; Rockafellow, I.; Sontag, D.; Alm, E.J. Predicting human health from biofluid-based metabolomics using machine learning. *Sci. Rep.* **2020**, *10*, 17635. [CrossRef]
20. Takeda, I.; Stretch, C.; Barnaby, P.; Bhatnager, K.; Rankin, K.; Fu, H.; Weljie, A.; Jha, N.; Slupsky, C. Understanding the human salivary metabolome. *NMR Biomed.* **2009**, *22*, 577–584. [CrossRef]
21. Mikkonen, J.J.; Singh, S.P.; Herrala, M.; Lappalainen, R.; Myllymaa, S.; Kullaa, A.M. Salivary metabolomics in the diagnosis of oral cancer and periodontal diseases. *J. Periodontol. Res.* **2016**, *51*, 431–437. [CrossRef] [PubMed]
22. Chiappin, S.; Antonelli, G.; Gatti, R.; De Palo, E.F. Saliva specimen: A new laboratory tool for diagnostic and basic investigation. *Clin. Chim. Acta* **2007**, *383*, 30–40. [CrossRef]
23. Dame, Z.T.; Aziat, F.; Mandal, R.; Krishnamurthy, R.; Bouatra, S.; Borzouie, S.; Guo, A.C.; Sajed, T.; Deng, L.; Lin, H.; et al. The human saliva metabolome. *Metabolomics* **2015**, *11*, 1864–1883. [CrossRef]
24. Pfaffe, T.; Cooper-White, J.; Beyerlein, P.; Kostner, K.; Punyadeera, C. Diagnostic potential of saliva: Current state and future applications. *Clin. Chem.* **2011**, *57*, 675–687. [CrossRef] [PubMed]
25. Hyvärinen, E.; Savolainen, M.; Mikkonen, J.J.W.; Kullaa, A.M. Salivary Metabolomics for Diagnosis and Monitoring Diseases: Challenges and Possibilities. *Metabolites* **2021**, *11*, 587. [CrossRef] [PubMed]
26. Gardner, A.; Carpenter, G.; So, P.W. Salivary Metabolomics: From Diagnostic Biomarker Discovery to Investigating Biological Function. *Metabolites* **2020**, *10*, 47. [CrossRef] [PubMed]
27. Khurshid, Z.; Zohaib, S.; Najeeb, S.; Zafar, M.S.; Slowey, P.D.; Almas, K. Human Saliva Collection Devices for Proteomics: An Update. *Int. J. Mol. Sci.* **2016**, *17*, 846. [CrossRef]
28. Silwood, C.; Lynch, E.; Claxson, A.; Grootveld, M. ¹H and ¹³C nmr spectroscopic analysis of human saliva. *J. Dent. Res.* **2002**, *81*, 422–427. [CrossRef]
29. Sugimoto, M.; Saruta, J.; Matsuki, C.; To, M.; Onuma, H.; Kaneko, M.; Soga, T.; Tomita, M.; Tsukinoki, K. Physiological and environmental parameters associated with mass spectrometry-based salivary metabolomic profiles. *Metabolomics* **2013**, *9*, 454–463. [CrossRef]
30. Human Metabolome Database. Available online: <https://hmdb.ca> (accessed on 29 January 2023).
31. Lukacs, J.; Largaespa, L. Explaining sex differences in dental caries prevalence: Saliva, hormones, and “life-history” etiologies. *Am. J. Hum. Biol.* **2006**, *18*, 540–555. [CrossRef]
32. Mueller, D.C.; Piller, M.; Niessner, R.; Scherer, M.; Scherer, G. Untargeted metabolomic profiling in saliva of smokers and nonsmokers by a validated GC-TOF-MS method. *J. Proteome Res.* **2014**, *13*, 1602–1613. [CrossRef] [PubMed]
33. Dallmann, R.; Viola, A.U.; Tarokh, L.; Cajochen, C.; Brown, S.A. The human circadian metabolome. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 2625–2629. [CrossRef] [PubMed]
34. Ishikawa, S.; Sugimoto, M.; Kitabatake, K.; Tu, M.; Sugano, A.; Yamamori, I.; Iba, A.; Yusa, K.; Kaneko, M.; Ota, S.; et al. Effect of Timing of Collection of Salivary Metabolomic Biomarkers on Oral Cancer Detection. *Amino Acids* **2017**, *49*, 761–770. [CrossRef]
35. Gardner, A.; Parkes, H.G.; So, P.-W.; Carpenter, G.H. Determining bacterial and host contributions to the human salivary metabolome. *J. Oral Microbiol.* **2019**, *11*, 1617014. [CrossRef]
36. Belstrøm, D. The salivary microbiota in health and disease. *J. Oral Microbiol.* **2020**, *12*, 1723975. [CrossRef]
37. Wishart, D.S.; Cheng, L.L.; Copié, V.; Edison, A.S.; Eghbalnia, H.R.; Hoch, J.C.; Gouveia, G.J.; Pathmasiri, W.; Powers, R.; Schock, T.B.; et al. NMR and Metabolomics—A Roadmap for the Future. *Metabolites* **2022**, *12*, 678. [CrossRef] [PubMed]
38. Gowda, G.A.N.; Djukovic, D. Overview of Mass Spectrometry-Based Metabolomics: Opportunities and Challenges. In *Mass Spectrometry in Metabolomics. Methods in Molecular Biology*, 1st ed.; Raftery, D., Ed.; Humana Press: New York, NY, USA, 2014; Volume 1198, pp. 3–12. [CrossRef]
39. Naz, S.; Moreira dos Santos, D.C.; García, A.; Barbas, C. Analytical protocols based on LC-MS, GC-MS and CE-MS for nontargeted metabolomics of biological tissues. *Bioanalysis* **2014**, *6*, 1657–1677. [CrossRef]
40. Drouin, N.; Ramautar, R. Capillary Electrophoresis-Mass Spectrometry for Metabolomics: Possibilities and Perspectives. *Adv. Exp. Med. Biol.* **2021**, *1336*, 159–178. [CrossRef] [PubMed]
41. Vignoli, A.; Ghini, V.; Meoni, G.; Licari, C.; Takis, P.G.; Tenori, L.; Turano, P.; Luchinat, C. High-Throughput Metabolomics by 1D NMR. *Angew. Chem. Int. Ed. Engl.* **2019**, *58*, 968–994. [CrossRef]
42. Zeki, Ö.C.; Eylem, C.C.; Reçber, T.; Kir, S.; Nemutlu, E. Integration of GC-MS and LC-MS for untargeted metabolomics profiling. *J. Pharm. Biomed. Anal.* **2020**, *190*, 113509. [CrossRef]
43. Emwas, A.H. The strengths and weaknesses of NMR spectroscopy and mass spectrometry with particular focus on metabolomics research. *Methods Mol. Biol.* **2015**, *1277*, 161–193. [CrossRef]
44. Marshall, D.D.; Powers, R. Beyond the paradigm: Combining mass spectrometry and nuclear magnetic resonance for metabolomics. *Prog. Nucl. Magn. Reson. Spectrosc.* **2017**, *100*, 1–16. [CrossRef] [PubMed]

45. Delvaux, A.; Rathahao-Paris, E.; Alves, S. Different ion mobility-mass spectrometry coupling techniques to promote metabolomics. *Mass. Spectrom. Rev.* **2022**, *41*, 695–721. [CrossRef] [PubMed]
46. Aristizabal-Henao, J.J.; Lemas, D.J.; Griffin, E.K.; Costa, K.A.; Camacho, C.; Bowden, J.A. Metabolomic Profiling of Biological Reference Materials using a Multiplatform High-Resolution Mass Spectrometric Approach. *J. Am. Soc. Mass. Spectrom.* **2021**, *32*, 2481–2489. [CrossRef] [PubMed]
47. Pezzatti, J.; Boccard, J.; Codesido, S.; Gagnebin, Y.; Joshi, A.; Picard, D.; González-Ruiz, V.; Rudaz, S. Implementation of liquid chromatography-high resolution mass spectrometry methods for untargeted metabolomic analyses of biological samples: A tutorial. *Anal. Chim. Acta* **2020**, *1105*, 28–44. [CrossRef]
48. Martias, C.; Baroukh, N.; Mavel, S.; Blasco, H.; Lefèvre, A.; Roch, L.; Montigny, F.; Gatien, J.; Schibler, L.; Dufour-Rainfray, D.; et al. Optimization of Sample Preparation for Metabolomics Exploration of Urine, Feces, Blood and Saliva in Humans Using Combined NMR and UHPLC-HRMS Platforms. *Molecules* **2021**, *26*, 4111. [CrossRef] [PubMed]
49. Psychogios, N.; Hau, D.D.; Peng, J.; Guo, A.C.; Mandal, R.; Bouatra, S.; Sinelnikov, I.; Krishnamurthy, R.; Eisner, R.; Gautam, B.; et al. The human serum metabolome. *PLoS ONE* **2011**, *6*, 16957. [CrossRef] [PubMed]
50. Bouatra, S.; Aziat, F.; Mandal, R.; Guo, A.C.; Wilson, M.R.; Knox, C.; Bjorn Dahl, T.C.; Krishnamurthy, R.; Saleem, F.; Liu, P.; et al. The human urine metabolome. *PLoS ONE* **2013**, *8*, e73076. [CrossRef]
51. WHO. International Programme on Chemical Safety Biomarkers in Risk Assessment: Validity and Validation. Environmental Health Criteria 222. Available online: <http://www.inchem.org/documents/ehc/ehc/ehc222.htm> (accessed on 16 April 2021).
52. Khurshid, Z.; Zafar, M.S.; Khan, R.S.; Najeeb, S.; Slowey, P.D.; Rehman, I.U. Role of Salivary Biomarkers in Oral Cancer Detection. *Adv. Clin. Chem.* **2018**, *86*, 23–70. [CrossRef]
53. Yan, S.-K.; Wei, B.; Lin, Z.; Yang, Y.; Zhou, Z.; Zhang, W. A metabonomic approach to the diagnosis of oral squamous cell carcinoma, oral lichen planus and oral leukoplakia. *Oral. Oncol.* **2008**, *44*, 477–483. [CrossRef]
54. Jou, Y.J.; Lin, C.; Lai, C.; Chen, C.H.; Kao, J.Y.; Chen, S.Y.; Tsai, M.-H.; Huang, S.-H.; Lin, C.-W. Proteomic identification of salivary transferrin as a biomarker for early detection of oral cancer. *Anal. Chim. Acta* **2010**, *681*, 41–48. [CrossRef] [PubMed]
55. Sugimoto, M.; Wong, D.T.; Hirayama, A.; Soga, T.; Tomita, M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. *Metabolomics* **2010**, *6*, 78–95. [CrossRef]
56. Wei, J.; Xie, G.; Zhou, Z.; Shi, P.; Qiu, Y.; Zheng, X.; Chen, T.; Su, M.; Zhao, A.; Jia, W. Salivary metabolite signatures of oral cancer and leukoplakia. *Int. J. Cancer* **2011**, *129*, 2207–2217. [CrossRef] [PubMed]
57. Wang, Q.; Gao, P.; Wang, X.; Duan, Y. Investigation and identification of potential biomarkers in human saliva for the early diagnosis of oral squamous cell carcinoma. *Clin. Chim. Acta* **2014**, *427*, 79–85. [CrossRef] [PubMed]
58. Wang, Q.; Gao, P.; Wang, X.; Duan, Y. The early diagnosis and monitoring of squamous cell carcinoma via saliva metabolomics. *Sci. Rep.* **2014**, *4*, 6802. [CrossRef]
59. Ishikawa, S.; Sugimoto, M.; Kitabatake, K.; Sugano, A.; Nakamura, M.; Kaneko, M.; Ota, S.; Hiwatari, K.; Enomoto, A.; Soga, T. Identification of salivary metabolomic biomarkers for oral cancer screening. *Sci. Rep.* **2016**, *6*, 31520. [CrossRef]
60. Ohshima, M.; Sugahara, K.; Kasahara, K.; Katakura, A. Metabolomic analysis of the saliva of Japanese patients with oral squamous cell carcinoma. *Oncol. Rep.* **2017**, *37*, 2727–2734. [CrossRef]
61. Lohavanichbut, P.; Zhang, Y.; Wang, P.; Gu, H.; Gowda, G.A.N.; Djukovic, D.; Buas, M.F.; Raftery, D.; Chen, C. Salivary Metabolite Profiling Distinguishes Patients with Oral Cavity Squamous Cell Carcinoma from Normal Controls. *PLoS ONE* **2018**, *13*, e0204249. [CrossRef]
62. Ishikawa, S.; Wong, D.T.W.; Sugimoto, M.; Gleber-Netto, F.O.; Li, F.; Tu, M.; Zhang, Y.; Akin, D.; Iino, M. Identification of salivary metabolites for oral squamous cell carcinoma and oral epithelial dysplasia screening from persistent suspicious oral mucosal lesions. *Clin. Oral Investig.* **2019**, *23*, 3557–3563. [CrossRef]
63. Sridharan, G.; Ramani, P.; Patankar, S.; Vijayaraghavan, R. Evaluation of Salivary Metabolomics in Oral Leukoplakia and Oral Squamous Cell Carcinoma. *J. Oral Pathol. Med.* **2019**, *48*, 299–306. [CrossRef]
64. Ishikawa, S.; Hiraka, T.; Kirii, K.; Sugimoto, M.; Shimamoto, H.; Sugano, A.; Kitabatake, K.; Toyoguchi, Y.; Kanoto, M.; Nemoto, K.; et al. Relationship between Standard Uptake Values of Positron Emission Tomography/Computed Tomography and Salivary Metabolites in Oral Cancer: A Pilot Study. *J. Clin. Med.* **2020**, *9*, 3958. [CrossRef] [PubMed]
65. Song, X.; Yang, X.; Narayanan, R.; Shankar, V.; Ethiraj, S.; Wang, X.; Duan, N.; Ni, Y.H.; Hu, Q.; Zare, R.N. Oral squamous cell carcinoma diagnosed from saliva metabolic profiling. *Proc. Natl. Acad. Sci. USA* **2020**, *117*, 16167–16173. [CrossRef] [PubMed]
66. de Sá Alves, M.; de Sá Rodrigues, N.; Bandeira, C.M.; Chagas, J.F.S.; Pascoal, M.B.N.; Nepomuceno, G.L.J.T.; da Silva Martinho, H.; Alves, M.G.O.; Mendes, M.A.; Dias, M.; et al. Identification of Possible Salivary Metabolic Biomarkers and Altered Metabolic Pathways in South American Patients Diagnosed with Oral Squamous Cell Carcinoma. *Metabolites* **2021**, *11*, 650. [CrossRef] [PubMed]
67. Tantray, S.; Sharma, S.; Prabhat, K.; Nasrullah, N.; Gupta, M. Salivary metabolite signatures of oral cancer and leukoplakia through gas chromatography-mass spectrometry. *J. Oral Maxillofac. Pathol.* **2022**, *26*, 31–37. [CrossRef] [PubMed]
68. Ozmeric, N. Advances in periodontal disease markers. *Clin. Chim. Acta* **2004**, *343*, 1–16. [CrossRef]
69. Barnes, V.M.; Ciancio, S.G.; Shibly, O.; Xu, T.; Devizio, W.; Trivedi, H.M.; Guo, L.; Jönsson, T.J. Metabolomics reveals elevated macromolecular degradation in periodontal disease. *J. Dent. Res.* **2011**, *90*, 1293–1297. [CrossRef]
70. Aimetti, M.; Cacciatore, S.; Graziano, A.; Tenori, L. Metabonomic analysis of saliva reveals generalized chronic periodontitis signature. *Metabolomics* **2012**, *8*, 465–474. [CrossRef]

71. Huang, Y.; Zhu, M.; Li, Z.; Sa, R.; Chu, Q.; Zhang, Q.; Zhang, H.; Tang, W.; Zhang, M.; Yin, H. Mass spectrometry-based metabolomic profiling identifies alterations in salivary redox status and fatty acid metabolism in response to inflammation and oxidative stress in periodontal disease. *Free Radic. Biol. Med.* **2014**, *70*, 223–232. [\[CrossRef\]](#)
72. Barnes, V.M.; Kennedy, A.D.; Panagakos, F.; Devizio, W.; Trivedi, H.M.; Jönsson, T.; Guo, L.; Cervi, S.; Scannapieco, F.A. Global Metabolomic Analysis of Human Saliva and Plasma from Healthy and Diabetic Subjects, with and without Periodontal Disease. *PLoS ONE* **2014**, *9*, e105181. [\[CrossRef\]](#)
73. Kuboniwa, M.; Sakanaka, A.; Hashino, E.; Bamba, T.; Fukusaki, E.; Amano, A. Prediction of Periodontal Inflammation via Metabolic Profiling of Saliva. *J. Dent. Res.* **2016**, *95*, 1381–1386. [\[CrossRef\]](#)
74. Ozeki, M.; Nozaki, T.; Aoki, J.; Bamba, T.; Jensen, K.R.; Murakami, S.; Toyoda, M. Metabolomic Analysis of Gingival Crevicular Fluid Using Gas Chromatography/Mass Spectrometry. *Mass. Spectrom.* **2016**, *5*, A0047. [\[CrossRef\]](#)
75. Rzeznik, M.; Triba, M.N.; Levy, P.; Jungo, S.; Botosoa, E.; Duchemann, B.; Le Moyec, L.; Bernaudin, J.F.; Savarin, P.; Guez, D. Identification of a discriminative metabolomic fingerprint of potential clinical relevance in saliva of patients with periodontitis using ¹H nuclear magnetic resonance (NMR) spectroscopy. *PLoS ONE* **2017**, *12*, e0182767. [\[CrossRef\]](#)
76. Liebsch, C.; Pitchika, V.; Pink, C.; Samietz, S.; Kastenmüller, G.; Artati, A.; Suhre, K.; Adamski, J.; Nauck, M.; Völzke, H.; et al. The Saliva Metabolome in Association to Oral Health Status. *J. Dent. Res.* **2019**, *98*, 642–651. [\[CrossRef\]](#)
77. Singh, M.P.; Saxena, M.; Saimbi, C.S.; Siddiqui, M.H.; Roy, R. Post-periodontal surgery propounds early repair salivary biomarkers by ¹H NMR based metabolomics. *Metabolomics* **2019**, *15*, 141. [\[CrossRef\]](#) [\[PubMed\]](#)
78. Romano, F.; Meoni, G.; Manavella, V.; Baima, G.; Mariani, G.M.; Cacciatore, S.; Tenori, L.; Aimetti, M. Effect of non-surgical periodontal therapy on salivary metabolic fingerprint of generalized chronic periodontitis using nuclear magnetic resonance spectroscopy. *Arch. Oral Biol.* **2019**, *97*, 208–214. [\[CrossRef\]](#) [\[PubMed\]](#)
79. Gawron, K.; Wojtowicz, W.; Łazarz-Bartyzel, K.; Łamasz, A.; Qasem, B.; Mydel, P.; Chomyszyn-Gajewska, M.; Potempa, J.; Mlynarz, P. Metabolomic Status of The Oral Cavity in Chronic Periodontitis. *In Vivo* **2019**, *33*, 1165–1174. [\[CrossRef\]](#)
80. Schulte, F.; King, O.D.; Paster, B.J.; Moscicki, A.B.; Yao, T.J.; Van Dyke, R.B.; Shiboski, C.; Ryder, M.; Seage, G.; Hardt, M. Pediatric HIV/AIDS Cohort Study. Salivary metabolite levels in perinatally HIV-infected youth with periodontal disease. *Metabolomics* **2020**, *16*, 98. [\[CrossRef\]](#) [\[PubMed\]](#)
81. Citterio, F.; Romano, F.; Meoni, G.; Iaderosa, G.; Grossi, S.; Sobrero, A.; Dego, F.; Corana, M.; Berta, G.N.; Tenori, L.; et al. Changes in the Salivary Metabolic Profile of Generalized Periodontitis Patients after Non-surgical Periodontal Therapy: A Metabolomic Analysis Using Nuclear Magnetic Resonance Spectroscopy. *J. Clin. Med.* **2020**, *9*, 3977. [\[CrossRef\]](#)
82. Rodrigues, W.F.; Miguel, C.B.; Agostinho, F.; da Silva, G.V.; Lazo-Chica, J.E.; Scapin, S.M.N.; Napimoga, M.H.; Trindade-da-Silva, C.A.; Krieger, J.E.; Pereira, A.D.C.; et al. Metabolomic Evaluation of Chronic Periodontal Disease in Older Adults. *Mediat. Inflamm.* **2021**, *2021*, 1796204. [\[CrossRef\]](#)
83. Overmyer, K.A.; Rhoads, T.W.; Merrill, A.E.; Ye, Z.; Westphall, M.S.; Acharya, A.; Shukla, S.K.; Coon, J.J. Proteomics, Lipidomics, Metabolomics, and 16S DNA Sequencing of Dental Plaque From Patients With Diabetes and Periodontal Disease. *Mol. Cell Proteom.* **2021**, *20*, 100126. [\[CrossRef\]](#)
84. Barros, S.P.; Williams, R.; Offenbacher, S.; Morelli, T. Gingival crevicular fluid as a source of biomarkers for periodontitis. *Periodontol 2000* **2016**, *70*, 53–64. [\[CrossRef\]](#) [\[PubMed\]](#)

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.